Anson Properties Ceases Substantial Stake in iX Biopharma

Anson Properties Reduces iX Biopharma Stake

Anson Properties has divested one million shares in Singapore-listed iX Biopharma (SGX: 42C), reducing its holding from 5.08% to 4.99%. This transaction, reported in an SGX filing on September 10, 2026, means Anson Properties is no longer classified as a substantial shareholder. The shares were sold for a total consideration of S$535,000, translating to an average price of 53.5 cents per share.

Wafermine Emergency Use Pathway Cleared

This share divestment occurs shortly after iX Biopharma announced on September 7, 2026, that the US government established an emergency use pathway for drugs. This pathway targets moderate-to-severe acute pain in military casualties.

The development clears the way for iX Biopharma to advance its emergency use authorisation (EUA) submission for its drug, Wafermine, to the US Food and Drug Administration (FDA). The company has confirmed that work on the EUA submission is currently underway.

iX Biopharma Shares See Daily Drop Amidst Strong Year-to-Date Gains

On September 10, 2026, iX Biopharma's shares closed 2.5 cents lower, marking a 4% decline to 60 cents per share. Despite this daily dip, the company's stock has demonstrated significant performance on a year-to-date basis, recording a substantial gain of 341%. This longer-term appreciation reflects considerable market interest in the biopharmaceutical firm's prospects.

Market Focus Shifts to EUA Submission Deadline

For investors in Singapore's market, Anson Properties' move to reduce its stake places renewed emphasis on iX Biopharma's drug development timeline. The company anticipates completing its Wafermine EUA submission to the FDA by the fourth quarter of 2026.

This upcoming deadline represents a key event that could significantly influence iX Biopharma's valuation and investor sentiment on the Singapore Exchange.